Abstract. Peroxiredoxin (Prx) I is an antioxidant protein expressed in proliferating cells.
Introduction
The peroxiredoxin (Prx) antioxidant protein family is found in a wide variety of species and plays important roles in protecting cells against oxidants and in regulating signaling by hydrogen peroxide. Its structure was recently reported and analyzed with respect to these dual roles 24 . At least six Prx enzymes are present in mammals (Prx I-VI) 15 . These Prx isoforms are found in the cytosol, mitochondria, peroxisomes, and plasma, all of which are potential sites of reactive oxygen species (ROS) production 3, 5, 8, 9, 12, 17 .
Pag (human Prx I) was originally isolated by differential screening of cDNA libraries made from untransformed and ras-transformed human mammary epithelial cells. Because these cells cease proliferating during the commitment phase of differentiation, the higher levels of pag gene expression were correlated with cell proliferation 13 . Furthermore, some reports show an association between Prx I and the protooncogene product c-Abl, Myc, and cell cycle factor cdc2 1, 23 . Taken together, these findings indicate that Prx I is associated with cell proliferation and tumor growth.
There are many reports of markers for proliferation, e.g., argynophilic nucleolar organizer regions (AgNORs), Ki67, and proliferating cell nuclear antigen (PCNA), that have been suggested to have clinical applications 7, 21, 22 . Although there are many reports on proliferation markers in the head and neck region, few focus on Prx I. We previously investigated oral squamous cell carcinoma and reported the potential usefulness of Prx I as a marker for clinicopathological features compared with PCNA 26 .
However these results were not sufficient for clinical applications, because the samples 
Patients and methods

Patients
Tumor specimens were obtained by punch biopsies of the tongue from 132 patients who consulted the Division of Head and Neck Surgery, Chiba Cancer Center Hospital, from 1970 to 1995. The clinical features of these patients are summarized in Table 1 .
The tumors were staged according to the International Union Against Cancer (UICC) scheme 19 . The characteristics of the tumors are also shown in Table 1 Gy). Local recurrence was defined as tumor recurrence in the primary region after primary treatment. Lymph node recurrence was defined as lymph node metastasis after primary treatment, including no treatment of the regional cervical lymph node. Lymph node metastasis was confirmed by histologically.
Methods
Immunostaining was performed using the horseradish peroxidase-labeled streptavidin and biotin technique. Control staining was performed with non-immune rabbit or mouse serum. As in our previous report, diseased thyroid tissues were immunoblotted as positive or negative controls for Prx I staining 26 . To confirm that the disparity in staining among sections was not due to the condition of samples, we divided the samples into old ones (collected before August 1986) and new ones (collected later than August 1986) and analyzed the groups statistically by the chi-square test. The positive-to-negative ratio in the old
samples was 26/40 and in the new samples was 27/39. Therefore, the disparity in staining was not significantly influenced by the time since fixation or the storage conditions (P = 0.86).
For univariate analysis, we used the chi-square test. For multivariate analysis, multiple logistic regression analysis was used. The analyses were performed using the StatView 5.0 statistical software package (SAS Institute Inc., Cary, NC, USA).
Results
Univariate analysis of Prx I expression and recurrence
Prx I expression was observed in the epithelium of the SCC in 79% of the specimens examined. To simplify the analysis for the correlation of Prx I expression with clinical features, the T-categories were divided into T1 + T2 and T3 + T4 groups, and the N-categories as lymph node metastasis negative (N0) and lymph node metastasis positive (N1+2) groups. The clinical stages were subclassified into stage I + II and stage III+IV. The differentiation status was divided into moderately or poorly differentiated (G2+G3) and well differentiated (G1). (Tables 3, 4 ).
Multivariate analysis of recurrence
Multivariate analysis was used next, to provide adjusted odds ratios for local and lymph node recurrence. The predictor variables for all 132 cases were used in a logistic regression model with local recurrence and lymph node recurrence as the dependant variables. A logistic model for predicting the local or lymph node recurrence was constructed using clinical variables, including age, sex, T-and N-category, stage, differentiation, tumor morphology, and Prx I expression. For simplicity, the tumor morphology classification was divided into two groups (endophytic or other). For our analysis of lymph node recurrence, we entered the use of neck irradiation and the use of neck dissection as forced variables to exclude the influence of therapeutic differences.
The adjusted odds ratios (OR) and 95% confidence intervals (CI) for local recurrence and lymph node recurrence are shown in Tables 5 and 6 . Prx I expression (OR = 2.84; 95% confidence interval: 1.09-7.43; P = 0.034) was significantly associated with local
recurrence, but the other predictors were not. The analysis of lymph node recurrence showed that Prx I expression (OR = 2.86; 95% confidence interval: 1.02-8.01; P = 0.046) and differentiation (OR = 3.77; 95% CI: 1.32-10.78; P = 0.013) were significantly associated, but the other predictors were not.
Discussion
In this study we found Prx I expression to be significantly associated with local recurrence (P = 0.033) by univariate analysis, and both local (OR = 2.84; 95%
confidence interval: 1.09-7.43; P = 0.034) and lymph node (OR = 2.86; 95% confidence interval: 1.02-8.01; P = 0.046) recurrence by multivariate analysis. These results indicate that Prx I expression predicts a 2.8-2.9-fold more frequent incidence of local and lymph node recurrence.
We can hypothesize why the Prx I-expressing tumors tended to recur. One explanation is that tumor recurrence may be ascribed to tumor viability. Prx I was originally isolated from proliferating cells 13 and Prx I overexpression has been reported in some tumors 6, 11 . These studies show that highly proliferative cells, like tumor cells, express more Prx I than do normal cells. Furthermore, among thyroid tumors, the more proliferative types of tumors tend to express more Prx I 25 . Taken together, these results support the association between Prx I and tumor viability.
Another explanation involves Prx I's ability to act as a tumor suppressor through the reduction of ROS. ROS and the reactive oxygen metabolites (ROM) that are formed in the process of cellular respiration are implicated in tumor formation and promotion.
By causing DNA damage, ROM are thought to affect protooncogenes and tumor suppressor genes 16 . Previous reports show that over-expression of Pag, human Prx I, counteracts the physiological role of the protooncogene abl, which has a cytostatic effect on cells. Elevated levels of Prx I in tumor cells seem to abrogate the abl-induced cell-cycle block 14, 23 . Recently, studies using a Prx I-knockout mouse indicated that Prx I expression was associated with oxidative damage and the presence of malignant neoplasms 10 . These findings indicated that in normal cells Prx I plays a direct role in tumor suppression by eliminating ROS and preventing oxidative damage 10 . Similarly, excessively proliferative tumor cells may express Prx I to protect themselves from oxidative damage.
The radiosensitivity of tumors may also be related to their recurrence through a mechanism involving Prx I. Many patients in this report were treated with radiotherapy.
Irradiation can induce Prx I expression, which protects cells from further radiation damage 2 . However, these results suggest that protection by Prx I may also play an important role in the survival of cancer cells in patients undergoing radiation therapy, and therefore the residual carcinoma may easily recur.
We previously reported the potential of using Prx I as a marker for clinicopathological features 26 . In that report, we determined Prx I expression in oral SCC in various regions by immunohistochemistry and found an association between Prx I expression and T and N classification. In the present report, we used a uniform sample type from only the tongue, and the measure of Prx I expression was changed to In this report, we have shown that Prx I may be useful as a tumor recurrence marker, which could be beneficial if applied clinically. For example, we could use it to estimate whether a tumor is susceptible to recurrence, and apply this information by making a wider area of excision or additional treatment, such as chemotherapy for positive tumors, to prevent recurrence. Further study is necessary to develop methods to apply Prx I as a marker for a more precise assessment of tongue SCC recurrence.
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